Conexeu Sciences Inc.
Nasdaq • Biotechnology
Key Finding: Conexeu Sciences (CNXU) is a recently public (May 2026) early-stage biotechnology company developing investigational collagen-based regenerative tissue scaffolds for aesthetics and wound care, exhibiting high stock volatility with one analyst Buy rating and pre-revenue financials.
Fact: Real-time price and metrics from Yahoo Finance. View live quote →
| Metric | Value |
|---|---|
| YTD Return | 11.92% |
| 1-Year Return | 11.92% (since listing) |
| Avg. Daily Volume | 93,369 (recent: 245,869) |
| Volume Today | 245,869 |
Interpretation: Strong intraday gains often tied to press releases; short trading history limits long-term assessment.
| Metric | Value |
|---|---|
| Revenue (TTM) | -- (pre-revenue) |
| Net Income (TTM) | -$7.2M |
| EPS (TTM) | -$0.34 |
| Total Cash (MRQ) | $6.85M |
| Total Debt/Equity | 0.05% |
| Price/Book (MRQ) | 35.32 |
| Profit Margin | 0.00% |
Interpretation: Typical early-stage biotech profile with significant cash burn and high valuation multiple reflecting growth expectations.
Links for more information:
• Historical stock performance (Yahoo Finance)
• Company website & investor relations
• Nasdaq official page
| Analyst | Date | Rating | Price Target |
|---|---|---|---|
| HC Wainwright & Co. | June 22, 2026 | Buy | $20.00 |
Interpretation: Limited coverage typical for newly listed micro-cap biotech; target implies ~68% upside from current price.
Uncertainty: No commercial customers or revenue-generating contracts disclosed yet. Products remain investigational/pending regulatory clearance.
Limited public disclosure of direct competitors. Likely peers in regenerative biomaterials and aesthetics include:
| Company | Ticker | Focus |
|---|---|---|
| Organogenesis | ORGO | Regenerative tissue products |
| Integra LifeSciences | IART | Tissue repair & regeneration |
| MiMedx | MDXG | Placental tissue allografts |
| Other aesthetics players | Various (e.g., RVNC, EOLS) | Injectables & fillers |
Interpretation: Differentiates via collagen ECM scaffolds positioned as alternatives to traditional fillers/implants.
Conexeu Sciences Inc. develops patented collagen-based extracellular matrix (ECM) scaffold products, including the CXU™ collagen gel platform. Focus areas: medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring. Products are investigational with preclinical/peer-reviewed data supporting tissue regeneration while minimizing inflammation/fibrosis.
Founded: 2022 | Headquarters: Reno, Nevada (R&D: Vancouver) | Employees: Small team (executives listed; early-stage)
Website: conexeu.com